Think globally, prescribe locally: How rational pharmaceutical policy in the U.S. can improve global access to essential medicines

American Journal of Law and Medicine

Volumn 34, Issue 2-3, 2008, Pages 125-139

  Kesselheim, Aaron S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL DRUG;

ARTICLE; HEALTH; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; PRESCRIPTION; UNITED STATES;

DRUG PRESCRIPTIONS; DRUGS, ESSENTIAL; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; UNITED STATES; WORLD HEALTH;

EID: 58149140509     PISSN: 00988588     EISSN: None     Source Type: Journal    
DOI: 10.1177/009885880803400203     Document Type: Conference Paper

References (110)

1. THE COMMISSION ON INTELLECTUAL PROPERTY RIGHTS, INNOVATION AND PUBLIC HEALTH, World Health Organization, PUBLIC HEALTH: INNOVATION AND INTELLECTUAL PROPERTY RIGHTS 8 (2006), www.who.int/ intellectualproperty/documents/thereport/ENPublicHealthReport.pdf.
2. Kevin Outterson & Aaron S. Kesselheim, Market-Based Licensing Proposal for HPV Vaccines in Developing Countries, 27 HEALTH AFF. 130,131 (2008).
3. Gavin Yamey, Faltering Steps Towards Partnerships, 325 BRIT. MED. J. 1236,1238 (2002).
4. Brook K. Baker, A Deadly Game of Pharmaceutical Apartheid, THE NATION (Thail.), Mar. 16, 2007.
5. John Clemens & Luis Jodar, Introducing New Vaccines into Developing Countries.: Obstacles, Opportunities and Complexities, NATURE MFD., Apr. 2005, at S12, S14.
6. WHO POLICY PERSPECTIVES ON MEDICINES, WORLD HEALTH ORGANIZATION, EQUITABLE ACCESS To ESSENTIAL MEDICINES: A FRAMEWORK FOR COLLECTIVE ACTION 1 (2004) whqlibdoc.who.int/hq/2004/WHO_EDM_2004.4.pdf.
7. MÉDICINS SANs FRONTIÈRES, SURMOUNTING CHALLENGES: PROCUREMENT OF ANTIRETROVIRAL MEDICINES IN LOW- AND MIDDLE-INCOME COUNTRIES 4 (2003), www.accessmed-msf.org/documents/ procurementreport.pdf.
8. Paul Farmer & Jim Y. Kim, Community Based Approaches to the Control of Multidrug Resistant Tuberculosis: Introducing DOTS-plus, 317 BRIT. MED. J. 671, 672 (1998).
9. Victoria G. Hale et al., Oxymoron No More: The Potential of Nonprofit Drug Companies to Deliver on the Promise of Medicines for the Developing World, 24 HEALTH AFF. 1057,1057 (2005).
10. JAMES LOVE & TIM HUBBARD, KNOWLEDGE ECOLOGY INTERNATIONAL, THE BIG IDEA: PRIZES TO STIMULATE R&D FOR NEW MEDICINES 11 (2007), www.keionline.org/misc-docs/bigidea-prizes.pdf.
11. MICHAEL KREMER & RACHEL GLENNERSTER, STRONG MEDICINE: CREATING INCENTIVES FOR PHARMACEUTICAL RESEARCH ON NEGLECTED DISEASES 45 (Princeton University Press 2004).
12. Marc Kaufman, FDA Scrutiny Scant in India, China as Drugs Pour into US: Broad Overseas Checks Called Too Costly, WASHINGTON POST, June 17, 2007, at A01.
13. Agreement on Trade-Related Aspects of Intellectual Property Rights art. 27.1, Apr. 15, 1994,33 I.L.M. 81.
14. Aaron S. Kesselheim & Jerry Avorn, University-Based Science and Biotechnology Research: Defining the Boundaries of Intellectual Property, 293 JAMA 850 (2005).
15. Aaron S. Kesselheim, Patents and Intellectual Property in Medicine, in LEGAL MEDICINE 207-13 (7th ed. Mosby Press 2007).
16. Kevin Outterson, Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets, 5 YALE J. HEALTH POLY L. & ETHICS 193, 196 (2005).
17. Sarah E. Eurek, Note, Hatch-Waxman Reform and Accelerated Market Entry of Generic Drugs: Is Faster Necessarily Better?, 18 DUKE L. & TECH. REV (2003), www.law.duke.edu/journals/dltr/articles/pdf/ 2003DLTROO18.pdf
18. Federal Trade Commission, Generic Drug Entry Prior to Patent Expiration, July 2002.
19. Eurek, supra note 17.
20. Id.
21. Drug Price Competition and Patent Term Restoration Act, Pub Law No. 98-417 (Sept. 24, 1984).
22. Id.
23. Aaron S. Kesselheim et al., Extensions of Intellectual Property Rights and Delayed Adoption of Generic Drugs: Effects on Medicaid Spending, 25 HEALTH AFF. 1637 (2006).
24. Rogers L. Williams, FDA Position on Product Selection for 'Narrow Therapeutic Index' Drugs, AM. J. HEALTH-SYS. PHARM., 1630, 1631 (1997).
25. Congressional Budget Office, How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry (Jul. 1998), www.cbo.gov/ftpdocs/6xx/doc655/pharm.pdf.
26. Richard G. Frank, The Ongoing Regulation of Generic Drugs, NEW ENG. J. MED 1993, 1993 (2007).
27. Michael A. Fischer & Jerry Avorn, Economic Consequences of Underuse of Generic Drugs: Evidence from Medicaid and Implications for Prescription Drug Benefit Plans, 38 Health Serv. Res. 1051, 1051 (2003)
28. Jennifer S. Haas et al., Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000, 142 ANN. INTERNAL MED. 891, 891 (2005).
29. Kesselheim et al., supra note 21, at 1640.
30. Michael A. Fischer & Jerry Avorn, Economic Implications of Evidence-Based Prescribing for Hypertension: Can Better Care Cost Less?, 291 JAMA 1850, 1850 (2004).
31. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, III Stat. 2296.
32. Kesselheim, supra note 26, at 1645.
33. Astra Aktiebolag v. Andrx Pharmaceuticals, Inc., 222 F. Supp. 2d 423, 423 (S.D.N.Y. 2002).
34. Schering Corp. v. Geneva Pharmaceuticals, 339 F.3d 1373, 1373 (Fed. Cir. 2003).
35. William H. Shrank et al., The Effect of Pharmacy Benefit Design on Patient-Physician Communication about Costs, 21 J. GEN. INTERNAL MED. 334, 334 (2006).
36. Melissa Healy, Under the Influence, L.A. TIMES, Aug 6, 2007, at F1.
37. Lisa D. Chew et al., A Physician Survey of the Effect of Drug Sample Availability on Physicians' Behavior, 15 J. GEN. INTERNAL MED. 478, 482 (2000) (concluding from the results of a study that physicians who receive drug samples may be prescribing these drug samples instead of drugs that physicians prefer).
38. John M. Boltri et al., Effect of Antihypertensive Samples on Physician Prescribing Patterns, 34 FAMILY MED. 729, 731 (2002).
39. William H. Shrank et al., Patient, Physician, Pharmacy, and Pharmacy Benefit Design Factors Related to Generic Medication Use, 22 J. GEN. INTERNAL MED. 1298, 1303 (2007).
40. W. Himmel et al., What do Primary Care Patients Think about Generic Drugs?; 43 INT'L J. CLINICAL PHARMACOLOGY THFRAPEUTICS 472, 476 (2005).
41. Janice Hopkins Tanne, U.S. Doctors and Patients are Split on Approval of Generic Thyroid Hormone, 329 BRIT. MED. J. 192, 192 (2004).
42. Frederick Andermann et al., Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug Classes, 48 EPILEPSIA 464, 469 (2007).
43. Although it is not clear in each case whether this is a true physiological response or may be a manifestation of patients' lack of confidence in generic drugs.
44. Silvia Alessi-Severini et al., Evaluation of an Interchangeability Switch in Patients Treated with Clozapine: A Retrospective Review, 67 J. CLINICAL PSYCHIATRY 1047, 1053 (2006)
45. Jennifer A. Pereira et al., Are Brand-Name and Generic Warfarin Interchangeable? Multiple N-of-1 Randomized, Crossover Trials, 39 ANNALS PHARMACOTHERAPY 1188, 1192 (2005)
46. Thomas L. Schwartz et al., Divalproex Sodium Versus Valproic Acid in Hospital Treatment of Psychotic Disorders, 2 PRIMARY CARE COMPANION TO J. CLINICAL PSYCHIATRY 45, 48 (2000).
47. HealthNewsDigest.com, Generic Antidepressant Behaves Differently from Original Drug, Oct. 12, 2007, healthnewsdigest.com/news/Research_270/ Generic_Antidepressant_Be↔ves_ Differently_from_Original_Drug∥inter.shtml
48. Bloomberg News, Generic Drug Maker Recalls All Its Products, N.Y. TIMES, May 24, 2005.
49. Press Release, Sidney M. Wolfe, Concerning Warner-Lambert Criminal Conviction and Poor Manufacturing Practices ... Includes Dilantin Recalls (HRG Publication #1380) (Nov. 29, 1995), www.citizen.org/ publications/release.cfm?ID=5555.
50. STEVEN SIMOENS & SANDRA DE COSTER, SUSTAINING GENERIC MEDICINES: MARKETS IN EUROPE 14 (2006), www.egagenerics.com/doc/ simoens-report_2006-04.pdf.
51. See Joseph A. Dimasi, New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Outputs of Pharmaceutical Firms, 34 DRUG INFO. J. 1169, 1169 (2000), available at www.diahome.org/content/abstract/2000/dijl556.pdf
52. Ramarao Desiraju, Diffusion of New Pharmaceutical Drugs in Developing and Developed Nations, May 24, 2004, faculty-gsb.stanford.edu/nair/ PDF-s/Diffusion_June_2004_Final.pdf
53. Micheal S. Rosen, The World's Top 50 Pharmaceutical Companies, May 27,2003, www.midwestbusiness.com/news/viewnews.asp?newsletterID=4649.
54. Kaufman, supra note 12, at A1.
55. GEOFF TANSEY, Introduction: Legal Fictions and Public Health, in NEGOTIATING HEALTH: INTELLECTUAL PROPERTY AND ACCESS TO MEDICINES 1, 2 (Pedro Roffe et al. eds., 2006).
56. Andrew Tanzer, Pill Factory to the World, FORBES, Dec. 10, 2001, at 70.
57. Luke Harding & Sarah Boseley, Dying for Drugs: Crusading Indian Firm Takes on Might of Glaxo SmithKline: Cipla is Offering Anti-Aids Drugs at a Fraction of Rivals' Prices, THE GUARDIAN (London), February 14, 2001, at 4.
58. Mary Pat Flahert et al., Testing Tidal Wave Hits Overseas; On Distant Shores, Drug Firms Avoid Delays - and Scrutiny, WASH. POST., December 18, 2000, at A01.
59. See U.S. CONGRESSIONAL BUDGET OFFICE, HOW INCREASED COMPETITION FROM GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY IX (July 1998), www.cbo.gov/ftpdocs/6xx/ doc655/pharm.pdf
60. Milt Freudenheim & Melody Petersen, The Drug-Price Express Runs Into a Wall, N.Y. TIMES, Dec. 23, 2001.
61. RANBAXY ANNUAL REPORT 6 (2002), www.ranbaxy.com/ investorinformation/annual_pr2002.aspx.
62. RANBAXY LABORATORIES LIMITED, GLOBAL OPERATIONS REPORT 19 (2004), www.ranbaxy.com/investorinformation/annual_pr2004.aspx.
63. Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, Annex 1C, Legal Instruments - Results of the Uruguay Round, 33 I.L.M. 1208 art. 31(b) (1994) [hereinafter "TRIPS Agreement"].
64. Celia Oh, TRIPS and Pharmaceuticals: A Case of Corporate Profits over Public Health, available at www.twnside.org.sg/title/twr12oa.htm ("Implementation of the TRIPS Agreement may lead to high drug prices, low access and a weakening of national pharmaceutical industries.").
65. Agreement on Trade-Related Aspects of Intellectual Property Rights, supra note 54.
66. Kevin Outterson & Aaron S. Kesselheim, Market Base Licensing for HPV Vaccine in Developing Countries, 21 HEALTH AFF. 130,133 (2008).
67. Bernard Pecoul et al., Access to Essential Drugs in Poor Countries: A Lost Battle?, 281 JAMA 361, 363 (1999).
68. Rajesh Gupta et al., Scaling Up Treatment for HIVIAIDS, 363 LANCET (London) 320, 321 (2004).
69. SUSAN FOSTER ET AL., DISEASE CONTROL PRINCIPLES IN DEVELOPING COUNTRIES ENSURING SUPPLIES OF APPROPRIATE DRUGS AND VACCINES 1326-27 (2nd ed. 2006).
70. 21 C.F.R. § 211.22 (2007) ("There shall be a quality control unit that shall have the responsibility and authority to approve or reject all components, drug product containers ... Adequate laboratory facilities ... shall be available to the quality control unit ... The quality control unit shall have the responsibility for approving or rejecting all procedures or specifications impacting on the identity, strength, quality, and purity of the drug product.").
71. Marc Kaufman, FDA Scrutiny Scant In India, China as Drugs Pour into U.S., WASH. POST, June 17,2007, at A01.
72. Amy S. Nunn et al., Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment, 4 PLoS MED. 1804,1805 (2007).
73. Michael A. Fischer et al., Impact of Medicaid Prior Authorization on Angiotensin-Receptor Blockers: Can Policy Promote Rational Prescribing?, 26 HEALTH AFF. 800, 805 (2007).
74. M.R. Cowie, Simultaneous Treatment of Hypertension and Dyslipidaemia May Help to Reduce Overall Cardiovascular Risk: Focus on Amlodipine/ Atorvastatin Single-Pill Therapy, 59 INT'L J. CLINICAL PRAC. 839, 844 (2005)
75. Marit D. Moen & Greg L. Plosker, Zolpidem Extended-Release, 20 CNS DRUGS 419, 420 (2006).
76. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin- Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 288 JAMA 2981, 2994(2002).
77. Roberto Cardarelli et al., A Cross-Sectional Evidence-Based Review of Pharmaceutical Promotional Marketing Brochures and Their Underlying Studies: Is What They Tell Us Important and True?, 7 BMC FAM. PRAC. (2006), www.boston.com/news/politics/politicalintelligence/ 2008/02/clinton_camp-an.html.
78. Id.
79. Id.
80. World Health Organization, The Commission on Intellectual Property Rights, Innovation and Public Health, supra note 1, at 19.
81. Salim Yusuf et al., Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation, 345 NEW ENG. J. MED. 494, 501 (2001).
82. Marilynn Marchione, New Heart Drug May Rival Plavix, ASSOCIATED PRESS. Nov 4, 2007.
83. Robert Steinbrook, Thailand and the Compulsory Licensing of Efavirenz, 356 NEW ENG. J. MED. 544,544-46 (2007).
84. Martin Vaughan, In Clash with Activists, Critics Charge Thailand Violation of Trade Rules, Intellectual Property Watch (Mar. 19, 2007), www.ipwatch.org/weblog/index.php?p=569
85. Press Release, Médecins Sans Frontières, Abbott Should Reconsider its Unacceptable Decision to Not Sell New Medicines in Thailand (Mar. 23, 2007), www.accessmed-msf.org/media-room/ press-releases/press-release-detail/article/ msf-abbott-should-reconsider-its-unacceptable-decision-to-not-sell-new- medicines-in-thailand/
86. S. REP. No. 301, at 27 (2007).
87. Press Release, Médecins Sans Frontières, supra note 74.
88. Miriam Shuchman, Delaying Generic Competition - Corporate Payoffs and the Future of Plavix, 355 NEW ENG. J. MED. 1297,1297 (2006).
89. Id.
90. Id.
91. Id.
92. Id.
93. id. at 1298.
94. BUREAU OF COMPETITION, FTC, AGREEMENTS FILED WITH THE FEDERAL TRADE COMMISSION UNDER THE MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, AND MODERNIZATION ACT OF 2003 (2007), www.fte.gov/reports/mmact/ MMAreport2oO6.pdf.
95. Kesselheim et al., supra note 26, at 1638.
96. See Geneva Pharm. v. GlaxoSmithKIine, 349 F.3d 1373 (Fed. Cir. 2003).
97. Kesselheim et al., supra note 26, at 1638.
98. Drug Price Competition and Patent Term Restoration Act, Pub.L. 98-417, 98 Stat. 1585 (1984).
99. Id.
100. NATIONAL INSTITUTE FOR HEALTH CARE MANAGEMENT FOUNDATION, PRESCRIPTION DRUGS AND INTELLECTUAL PROPERTY PROTECTION: FINDING THE RIGHT BALANCE BETWEEN ACCESS AND INNOVATION I (Aug. 2000), www.cptech.org/ip/health/econ/nihcm-drugs&ipp.pdf
101. Id.
102. Amy Kapczynski et al., Addressing Global Health Inequities: An Open Licensing Approach for University Innovations, 20 Berkeley Tech. L.J. 1031,1090 (2005).
103. Outterson & Kesselheim, supra note 2, at 134.
104. Robert Steinbrook, Closing the Affordability Gap for Drugs in Low-Income Countries, 357 NEW ENG. J. MED. 1996,1997 (2007)
105. TRIPS Agreement, supra note 54, at art. 27(1).
106. Janice M. Mueller, Taking TPIPS to India - Novartis, Patent Law, and Access to Medicines, 356 NEW ENG. J. MED. 541, 542 (2007).
107. Id. at 543.
108. Tahir Amin, India's Patent Act on Trial, I BRIDGES 15, 15 (2007), www.iprsonline.org/ictsd/news/bridgesll-l.pgl5-16.pdf.
109. 35 U.S.C. 103 (2004).
110. Aaron S. Kesselheim, Intellectual Property Policy in the Pharmaceutical Sciences: The Effect of Inappropriate Patents and Market Exclusivity Extensions on the Health Care System, 9 AAPS J. E 306, E308 (2007).